University of Waterloo   Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4
Founded: Waterloo Canada (1956)

Organization Overview

First Clinical Trial
2007
NCT00520351
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Associate Professor, University of Waterloo | CCLR, University of Waterloo | Centre for Contact Lens Research | Centre for Ocular Research & Education | Kinesiology and Health Sciences, University of Waterloo | University of Waterloo

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Diseases (Phase 2)

Brain Infarction (Phase 2)

Brain Ischemia (Phase 2)

Central Nervous System Diseases (Phase 2)

Cerebral Infarction (Phase 2)

Cerebrovascular Disorders (Phase 2)

Dry Eye Syndromes (Phase 4)

Glaucoma (Phase 4)

Hemorrhage (Phase 3)

Infarction (Phase 2)

Keratoconjunctivitis Sicca (Phase 4)

Myopia (Phase 3)

Nervous System Diseases (Phase 2)

Postpartum Hemorrhage (Phase 3)

Stroke (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 19